[SCHEDULE 13D/A] Elevation Oncology, Inc. Common stock SEC Filing

Rhea-AI Filing Summary

BML Investment Partners, L.P. has filed Amendment No. 1 to Schedule 13D regarding its prior position in Elevation Oncology, Inc. (ELEV). The filing states that, as of 23 July 2025, a Merger Agreement was consummated through a tender offer by an unaffiliated “Merger Sub” that purchased all outstanding shares of Elevation Oncology common stock. Following the closing, BML Investment Partners reports 0 shares beneficially owned, representing 0 % of the class.
• Voting and dispositive power: 0 shares sole or shared.
• Source of funds: “WC” (working capital) is listed, but no new capital was deployed as the position has been exited.
• No contracts, arrangements, or legal proceedings related to the securities are disclosed, and the reporting persons confirm no criminal or civil violations within the past five years.

The amendment principally serves to formally terminate BML’s reporting obligations by documenting its complete divestiture after the successful tender offer.

Positive

• Tender offer closed, indicating transaction completion and cash liquidity for former ELEV shareholders.

Negative

• Reporting person now holds 0 % of ELEV, reflecting total exit and eliminating this investor’s oversight or support.

Insights

Equity Analyst

TL;DR: BML exits ELEV post-merger; ownership now 0 %, signalling deal completion.

The amendment confirms that a full tender offer closed on 23 Jul 2025, removing Elevation Oncology’s public float. BML’s stake is now zero, ending its influence and reporting duties. For investors, the key takeaway is that the acquisition process has settled, likely leading to cash-out of former minority holders or a transition to a new corporate structure (private or combined entity). Absent price terms, the filing is informational rather than valuation-changing. Overall impact on remaining public shareholders is neutral, but it marks a liquidity event.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Elevation Oncology, Inc.

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

28623U101

(CUSIP Number)

Braden M Leonard
65 E Cedar - Suite2,
Zionsville, IN, 46077
317-344-2447

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/23/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 28623U101

1

Name of reporting person

BML Investment Partners, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common stock, par value $0.0001 per share
(b)	Name of Issuer: Elevation Oncology, Inc.
(c)	Address of Issuer's Principal Executive Offices: 101 Federal Street, Boston, UNITED STATES , 02110.
Item 2.	Identity and Background
(a)	Braden M. Leonard Mr. Leonard's business address is 65 E Cedar Suite 2, Zionsville, IN 46077. Mr. Leonard's principal business is to serve as managing member of BML Capital Management, LLC.
(b)	65 E Cedar - Suite 2, Zionsville IN 46077
(c)	See above.
(d)	During the past five years, none of BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or a party to a civil proceeding of a judicial or administrative body of competent jurisdiction where as a result of such proceeding BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(e)	During the past five years, none of BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or a party to a civil proceeding of a judicial or administrative body of competent jurisdiction where as a result of such proceeding BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	Braden M. Leonard is a citizen of the United States of America.
Item 3.	Source and Amount of Funds or Other Consideration
	n/a
Item 4.	Purpose of Transaction
	Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on July 23, 2025, Merger Sub completed a tender offer to purchase all of the Companys outstanding shares of common stock.
Item 5.	Interest in Securities of the Issuer
(a)	N/A
(b)	NONE
(c)	None of the Reporting Persons has effected any transactions in the Issuer's Common Stock during the 60 days preceding the date of this Schedule 13D.
(d)	Braden M Leonard is the Managing Member of BML Capital Management, LLC, which is the General Partner to BML Investment Partners, L.P.
(e)	N/A
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	To the best of the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between the Reporting Persons and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BML Investment Partners, L.P.

Signature:	Braden M Leonard
Name/Title:	Braden M Leonard - Managing Member of BML Capital Management, LLC
Date:	07/28/2025

FAQ

What did BML Investment Partners report in the Schedule 13D/A for ELEV?

It reported 0 shares beneficially owned, or 0 % of Elevation Oncology's common stock.

Why was the Schedule 13D amended?

To reflect BML’s complete divestiture after the tender offer closed on 23 Jul 2025.

What event triggered the filing?

Completion of a Merger Agreement and tender offer that acquired all outstanding ELEV shares.

Does BML have any voting or dispositive power left in ELEV?

No. Both voting and dispositive power are zero following the transaction.

Are there any ongoing contracts or arrangements between BML and Elevation Oncology?

The filing states there are no contracts, arrangements, or understandings regarding ELEV securities.